Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Diabetic Macular Edema-Pipeline Review, H1 2015

Diabetic Macular Edema-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Diabetic Macular Edema-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Diabetic Macular Edema-Pipeline Review, H1 2015', provides an overview of the Diabetic Macular Edema's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Diabetic Macular Edema and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Diabetic Macular Edema pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Diabetic Macular Edema Overview 8

Therapeutics Development 9

Pipeline Products for Diabetic Macular Edema-Overview 9

Pipeline Products for Diabetic Macular Edema-Comparative Analysis 10

Diabetic Macular Edema-Therapeutics under Development by Companies 11

Diabetic Macular Edema-Therapeutics under Investigation by Universities/Institutes 15

Diabetic Macular Edema-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Diabetic Macular Edema-Products under Development by Companies 20

Diabetic Macular Edema-Products under Investigation by Universities/Institutes 23

Diabetic Macular Edema-Companies Involved in Therapeutics Development 24

ActiveSite Pharmaceuticals, Inc. 24

Acucela Inc. 25

Aerpio Therapeutics, Inc. 26

Alcon, Inc. 27

Allergan, Inc. 28

AlphaMab Co., Ltd 29

Ampio Pharmaceuticals, Inc. 30

Astellas Pharma Inc. 31

Auven Therapeutics Management L.L.L.P 32

Avalanche Biotechnologies, Inc. 33

Eleven Biotherapeutics Inc. 34

F. Hoffmann-La Roche Ltd. 35

Foamix Pharmaceuticals Ltd. 36

Gene Signal International SA 37

Genmab A/S 38

GlaxoSmithKline plc 39

Icon Bioscience, Inc. 40

Kala Pharmaceuticals, Inc. 41

Kowa Company, Ltd. 42

Mabion SA 43

MacuCLEAR, Inc. 44

Molecular Design International, Inc. 45

NicOx S.A. 46

Ohr Pharmaceutical Inc. 47

Pfizer Inc. 48

Quark Pharmaceuticals, Inc. 49

Regeneron Pharmaceuticals, Inc. 50

Santen Pharmaceutical Co., Ltd. 51

SciFluor Life Sciences, LLC 52

Senju Pharmaceutical Co., Ltd. 53

ThromboGenics NV 54

Diabetic Macular Edema-Therapeutics Assessment 55

Assessment by Monotherapy Products 55

Assessment by Target 56

Assessment by Mechanism of Action 58

Assessment by Route of Administration 60

Assessment by Molecule Type 62

Drug Profiles 64

49-B-Drug Profile 64

abicipar pegol-Drug Profile 66

aganirsen-Drug Profile 68

AKB-9778-Drug Profile 70

ALG-1001-Drug Profile 72

Antibodies to Inhibit Hemopexin for Diabetic Macular Edema-Drug Profile 74

ASP-440-Drug Profile 75

ASP-8232-Drug Profile 77

AVA-101-Drug Profile 78

conbercept-Drug Profile 80

danazol-Drug Profile 82

darapladib-Drug Profile 83

dexamethasone acetate nanoparticle-Drug Profile 85

dexamethasone dipropionate-Drug Profile 87

difluprednate-Drug Profile 88

Drug for Diabetic Macular Edema-Drug Profile 89

Drugs to Inhibit Tyrosine Kinase for Ophthalmology-Drug Profile 90

EBI-029-Drug Profile 91

EBI-031-Drug Profile 92

emixustat hydrochloride-Drug Profile 93

KVD-001-Drug Profile 95

LKA-651-Drug Profile 96

loteprednol etabonate-Drug Profile 97

MC-4001-Drug Profile 98

minocycline Gel-Drug Profile 99

MTP-131-Drug Profile 100

NCX-422-Drug Profile 102

NCX-434-Drug Profile 103

nesvacumab-Drug Profile 104

ocriplasmin (recombinant)-Drug Profile 106

Peptide for Diabetic Macular Edema-Drug Profile 109

PF-04634817-Drug Profile 110

PF-655-Drug Profile 111

ranibizumab-Drug Profile 113

ranibizumab biosimilar-Drug Profile 116

ranibizumab biosimilar-Drug Profile 117

ripasudil-Drug Profile 118

RX-10045-Drug Profile 119

SF-0166-Drug Profile 121

Small Molecule to Inhibit Kallikrein for AMD and DME-Drug Profile 122

Small Molecules to Inhibit Plasma Kallikrein for DME and HAE-Drug Profile 123

Small Molecules to Inhibit VAP-1 for Diabetic Macular Edema-Drug Profile 125

squalamine lactate-Drug Profile 126

teprotumumab-Drug Profile 129

Diabetic Macular Edema-Recent Pipeline Updates 132

Diabetic Macular Edema-Dormant Projects 162

Diabetic Macular Edema-Discontinued Products 164

Diabetic Macular Edema-Product Development Milestones 165

Featured News & Press Releases 165

Appendix 173

Methodology 173

Coverage 173

Secondary Research 173

Primary Research 173

Expert Panel Validation 173

Contact Us 174

Disclaimer 174

List of Tables

Number of Products under Development for Diabetic Macular Edema, H1 2015 12

Number of Products under Development for Diabetic Macular Edema-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Development by Companies, H1 2015 (Contd..2) 17

Number of Products under Investigation by Universities/Institutes, H1 2015 18

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Development, H1 2015 21

Comparative Analysis by Unknown Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Products under Investigation by Universities/Institutes, H1 2015 26

Diabetic Macular Edema-Pipeline by ActiveSite Pharmaceuticals, Inc., H1 2015 27

Diabetic Macular Edema-Pipeline by Acucela Inc., H1 2015 28

Diabetic Macular Edema-Pipeline by Aerpio Therapeutics, Inc., H1 2015 29

Diabetic Macular Edema-Pipeline by Alcon, Inc., H1 2015 30

Diabetic Macular Edema-Pipeline by Allergan, Inc., H1 2015 31

Diabetic Macular Edema-Pipeline by AlphaMab Co., Ltd, H1 2015 32

Diabetic Macular Edema-Pipeline by Ampio Pharmaceuticals, Inc., H1 2015 33

Diabetic Macular Edema-Pipeline by Astellas Pharma Inc., H1 2015 34

Diabetic Macular Edema-Pipeline by Auven Therapeutics Management L.L.L.P, H1 2015 35

Diabetic Macular Edema-Pipeline by Avalanche Biotechnologies, Inc., H1 2015 36

Diabetic Macular Edema-Pipeline by Eleven Biotherapeutics Inc., H1 2015 37

Diabetic Macular Edema-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 38

Diabetic Macular Edema-Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 39

Diabetic Macular Edema-Pipeline by Gene Signal International SA, H1 2015 40

Diabetic Macular Edema-Pipeline by Genmab A/S, H1 2015 41

Diabetic Macular Edema-Pipeline by GlaxoSmithKline plc, H1 2015 42

Diabetic Macular Edema-Pipeline by Icon Bioscience, Inc., H1 2015 43

Diabetic Macular Edema-Pipeline by Kala Pharmaceuticals, Inc., H1 2015 44

Diabetic Macular Edema-Pipeline by Kowa Company, Ltd., H1 2015 45

Diabetic Macular Edema-Pipeline by Mabion SA, H1 2015 46

Diabetic Macular Edema-Pipeline by MacuCLEAR, Inc., H1 2015 47

Diabetic Macular Edema-Pipeline by Molecular Design International, Inc., H1 2015 48

Diabetic Macular Edema-Pipeline by NicOx S.A., H1 2015 49

Diabetic Macular Edema-Pipeline by Ohr Pharmaceutical Inc., H1 2015 50

Diabetic Macular Edema-Pipeline by Pfizer Inc., H1 2015 51

Diabetic Macular Edema-Pipeline by Quark Pharmaceuticals, Inc., H1 2015 52

Diabetic Macular Edema-Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 53

Diabetic Macular Edema-Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015 54

Diabetic Macular Edema-Pipeline by SciFluor Life Sciences, LLC, H1 2015 55

Diabetic Macular Edema-Pipeline by Senju Pharmaceutical Co., Ltd., H1 2015 56

Diabetic Macular Edema-Pipeline by ThromboGenics NV, H1 2015 57

Assessment by Monotherapy Products, H1 2015 58

Number of Products by Stage and Target, H1 2015 60

Number of Products by Stage and Mechanism of Action, H1 2015 62

Number of Products by Stage and Route of Administration, H1 2015 64

Number of Products by Stage and Molecule Type, H1 2015 66

Diabetic Macular Edema Therapeutics-Recent Pipeline Updates, H1 2015 135

Diabetic Macular Edema-Dormant Projects, H1 2015 165

Diabetic Macular Edema-Dormant Projects (Contd..1), H1 2015 166

Diabetic Macular Edema-Discontinued Products, H1 2015 167

List of Figures

Number of Products under Development for Diabetic Macular Edema, H1 2015 12

Number of Products under Development for Diabetic Macular Edema-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Products, H1 2015 21

Assessment by Monotherapy Products, H1 2015 58

Number of Products by Top 10 Targets, H1 2015 59

Number of Products by Stage and Top 10 Targets, H1 2015 59

Number of Products by Top 10 Mechanism of Actions, H1 2015 61

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 61

Number of Products by Top 10 Routes of Administration, H1 2015 63

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 63

Number of Products by Top 10 Molecule Types, H1 2015 65

Number of Products by Stage and Top 10 Molecule Types, H1 2015 65

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

ActiveSite Pharmaceuticals, Inc.

Acucela Inc.

Aerpio Therapeutics, Inc.

Alcon, Inc.

Allergan, Inc.

AlphaMab Co., Ltd

Ampio Pharmaceuticals, Inc.

Astellas Pharma Inc.

Auven Therapeutics Management L.L.L.P

Avalanche Biotechnologies, Inc.

Eleven Biotherapeutics Inc.

F. Hoffmann-La Roche Ltd.

Foamix Pharmaceuticals Ltd.

Gene Signal International SA

Genmab A/S

GlaxoSmithKline plc

Icon Bioscience, Inc.

Kala Pharmaceuticals, Inc.

Kowa Company, Ltd.

Mabion SA

MacuCLEAR, Inc.

Molecular Design International, Inc.

NicOx S.A.

Ohr Pharmaceutical Inc.

Pfizer Inc.

Quark Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Santen Pharmaceutical Co., Ltd.

SciFluor Life Sciences, LLC

Senju Pharmaceutical Co., Ltd.

ThromboGenics NV

Diabetic Macular Edema Therapeutic Products under Development, Key Players in Diabetic Macular Edema Therapeutics, Diabetic Macular Edema Pipeline Overview, Diabetic Macular Edema Pipeline, Diabetic Macular Edema Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com